Avenanthramides Market by Region: North America, Europe, Asia Pacific Trends

The global avenanthramides market size was valued at USD 134.7 million in 2024 and is forecast to reach USD 295.0 million by 2033, expanding at a CAGR of 9.3% from 2025 to 2033. Growth is driven by rising demand from the cosmetic, pharmaceutical, and nutraceutical industries, all of which are seeking natural, scientifically supported anti-inflammatory ingredients. Increasing patent activity, clinical progress, and stronger consumer interest in oat-derived actives are boosting adoption. However, limited raw material availability and technically demanding extraction processes continue to keep prices high and motivate greater investment in specialized production capabilities.

Consumers increasingly prefer natural ingredients with clinical validation, while formulators value avenanthramides for their combined antioxidant and anti-inflammatory attributes. Pharmaceutical interest is also increasing as early clinical findings confirm favorable safety profiles. Premium positioning enables higher margins, encouraging ingredient suppliers and biotech companies to pursue innovations in extraction, standardization, and formulation stability. Demand is concentrated in North America, Europe, and the Asia Pacific region, where skincare markets and regulatory frameworks are well developed. Even so, growth is moderated by restricted access to avenanthramide-rich oat bran, inconsistent phytochemical yields among oat cultivars, and high purification costs. Smaller producers encounter challenges scaling GMP-compliant manufacturing, while larger companies secure intellectual property and long-term sourcing contracts to protect competitive advantages. Strategic R&D collaborations and contract manufacturing agreements help reduce supply risks and accelerate commercialization, with investors supporting scale-up efforts.

Personalized beauty and nutrition trends are further shaping the market. Brands are updating formulations with bioactive ingredients that target specific concerns, including sensitive skin, eczema, and inflammation linked to lifestyle factors. Because avenanthramides are rare and validated by scientific research, they enable companies to differentiate their products in a competitive landscape.

Sustainability is also influencing purchasing decisions. Oats are considered a relatively low-impact crop, making avenanthramide sourcing compatible with clean-label and eco-conscious strategies. This sustainability alignment enhances consumer confidence, supports premium pricing, and strengthens avenanthramides’ position in advanced cosmeceuticals and functional health solutions.

Key Market Trends & Insights

• Asia Pacific led the market with a 43.0% revenue share in 2024.
• China accounted for over 90.7% of the Asia Pacific avenanthramides market.
• By product, the synthetic segment dominated with a 93.3% revenue share in 2024.
• By end-use, personal care and cosmetics represented 57.9% of total revenue in 2024.

Download a free sample PDF of the Avenanthramides Market Intelligence Study by Grand View Research.

Market Size & Forecast

• 2024 Market Size: USD 134.7 Million
• 2033 Projected Market Size: USD 295.0 Million
• CAGR (2025–2033): 9.3%
• Asia Pacific: Largest market in 2024

Competitive Landscape

The market is dominated by two major manufacturers: Ceapro Inc. and Cosciens Biopharma Inc.

• Ceapro Inc. is a biotechnology company specializing in the development and commercialization of oat-derived active ingredients, including avenanthramides. The company emphasizes technological innovation and proprietary extraction techniques to deliver high-purity bioactives for the personal care, nutraceutical, and pharmaceutical sectors. Its operations are anchored in research-driven quality and clinical validation. Ceapro’s commitment to sustainability and advanced processing supports its leadership in natural bioactives and enables continued innovation across multiple industries.
• Cosciens Biopharma Inc. is a clinical-stage biopharmaceutical firm focused on plant-derived bioactive compounds for anti-inflammatory and therapeutic use. It relies on clinical research to support the safety and efficacy of avenanthramides and other investigational compounds. Cosciens emphasizes scientific rigor and strategic partnerships to progress candidates through early clinical phases. Combining modern biotechnology with natural product development, the company aims to create novel therapeutic opportunities while addressing unmet needs in inflammation-related health conditions.

Prominent Companies

• Ceapro Inc.
• Cosciens Biopharma Inc.
• Chemicea Pharma
• Symrise AG
• Chen LanngBio
• Henan Steeda Industrial Co., Ltd.
• BioCrick

Explore Horizon Databook – the world’s most comprehensive market intelligence platform by Grand View Research.

Conclusion

The avenanthramides market is poised for substantial long-term growth, supported by rising demand for natural, clinically validated anti-inflammatory ingredients across personal care, nutraceutical, and pharmaceutical applications. Although limited raw material supply and complex extraction processes create production challenges, continued investment in advanced processing, strategic R&D collaborations, and sustainable sourcing initiatives is strengthening the industry’s foundation. With strong regional momentum in Asia Pacific and ongoing premiumization trends, avenanthramides are set to remain a high-value bioactive ingredient driving innovation in both skincare and health-focused product categories.